According to China Pharmaceutical's announcement, the company sued Tibet's Tiansheng and Xu Panfeng over Henan GM's performance compensation contract dispute. The second trial of the case upheld the original judgment. Currently, the judgment is being executed, and the amount involved is 139 million yuan. As of the date of disclosure of the announcement, the company had received a total of 101.2095 million yuan in principal and interest payments from Tibet Tiansheng, Henan GM received a payment of 5.0 million yuan from Tibet Tiansheng, the company's equity transfer payments due to Tibet Tiansheng of 16.881,000 yuan, and interest was offset by an amount equal to the remaining unpaid amount from Tibet Tiansheng. The company has carried out relevant accounting processing in the early stages, and will carry out corresponding accounting treatment based on the execution results in the future.

According to China Pharmaceutical's announcement, the company sued Tibet's Tiansheng and Xu Panfeng over Henan GM's performance compensation contract dispute. The second trial of the case upheld the original judgment. Currently, the judgment is being executed, and the amount involved is 139 million yuan. As of the date of disclosure of the announcement, the company had received a total of 101.2095 million yuan in principal and interest payments from Tibet Tiansheng, Henan GM received a payment of 5.0 million yuan from Tibet Tiansheng, the company's equity transfer payments due to Tibet Tiansheng of 16.881,000 yuan, and interest was offset by an amount equal to the remaining unpaid amount from Tibet Tiansheng. The company has carried out relevant accounting processing in the early stages, and will carry out corresponding accounting treatment based on the execution results in the future.